145 related articles for article (PubMed ID: 12234503)
1. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6.
Iversen P; Tammela TL; Vaage S; Lukkarinen O; Lodding P; Bull-Njaa T; Viitanen J; Hoisaeter P; Lundmo P; Rasmussen F; Johansson JE; Persson BE; Carroll K;
Eur Urol; 2002 Sep; 42(3):204-11. PubMed ID: 12234503
[TBL] [Abstract][Full Text] [Related]
2. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
Tyrrell CJ; Payne H; See WA; McLeod DG; Wirth MP; Iversen P; Armstrong J; Morris C;
Radiother Oncol; 2005 Jul; 76(1):4-10. PubMed ID: 16145740
[TBL] [Abstract][Full Text] [Related]
3. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
See WA; Wirth MP; McLeod DG; Iversen P; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Vaage S; Tammela TL; Lukkarinen O; Persson BE; Carroll K; Kolvenbag GJ;
J Urol; 2002 Aug; 168(2):429-35. PubMed ID: 12131282
[TBL] [Abstract][Full Text] [Related]
4. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
Wirth M; Tyrrell C; Wallace M; Delaere KP; Sánchez-Chapado M; Ramon J; Hetherington J; Pina F; Heynes CF; Borchers TM; Morris T; Stone A
Urology; 2001 Aug; 58(2):146-51. PubMed ID: 11489683
[TBL] [Abstract][Full Text] [Related]
5. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
Wirth M; Tyrrell C; Delaere K; Sánchez-Chapado M; Ramon J; Wallace DM; Hetherington J; Pina F; Heyns C; Borchers T; Morris T; Armstrong J;
Prostate Cancer Prostatic Dis; 2005; 8(2):194-200. PubMed ID: 15931272
[TBL] [Abstract][Full Text] [Related]
6. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
See WA; Tyrrell CJ;
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
[TBL] [Abstract][Full Text] [Related]
7. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
Tyrrell CJ; Kaisary AV; Iversen P; Anderson JB; Baert L; Tammela T; Chamberlain M; Webster A; Blackledge G
Eur Urol; 1998; 33(5):447-56. PubMed ID: 9643663
[TBL] [Abstract][Full Text] [Related]
8. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
[TBL] [Abstract][Full Text] [Related]
9. Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.
See W; Iversen P; Wirth M; McLeod D; Garside L; Morris T
Eur Urol; 2003 Nov; 44(5):512-7; discussion 517-8. PubMed ID: 14572747
[TBL] [Abstract][Full Text] [Related]
10. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
Iversen P; Johansson JE; Lodding P; Lukkarinen O; Lundmo P; Klarskov P; Tammela TL; Tasdemir I; Morris T; Carroll K;
J Urol; 2004 Nov; 172(5 Pt 1):1871-6. PubMed ID: 15540741
[TBL] [Abstract][Full Text] [Related]
11. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
McLeod DG; See WA; Klimberg I; Gleason D; Chodak G; Montie J; Bernstein G; Morris C; Armstrong J
J Urol; 2006 Jul; 176(1):75-80. PubMed ID: 16753373
[TBL] [Abstract][Full Text] [Related]
12. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.
Wirth M; Tyrrell C; Delaere K; Sánchez-Chapado M; Ramon J; Wallace DM; Hetherington J; Pina F; Heyns CF; Navani S; Armstrong J
Prostate Cancer Prostatic Dis; 2007; 10(1):87-93. PubMed ID: 17102802
[TBL] [Abstract][Full Text] [Related]
13. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Iversen P; Wirth MP; See WA; McLeod DG; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Lundmo P; Tammela TL; Johansson JE; Morris T; Carroll K;
Urology; 2004 May; 63(5):928-33. PubMed ID: 15134983
[TBL] [Abstract][Full Text] [Related]
14. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
Wirth MP; See WA; McLeod DG; Iversen P; Morris T; Carroll K;
J Urol; 2004 Nov; 172(5 Pt 1):1865-70. PubMed ID: 15540740
[TBL] [Abstract][Full Text] [Related]
15. Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.
Wellington K; Keam SJ
Drugs; 2006; 66(6):837-50. PubMed ID: 16706554
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
Wellington K; Keam SJ
Drugs Aging; 2007; 24(2):169-71. PubMed ID: 17313204
[TBL] [Abstract][Full Text] [Related]
17. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.
Iversen P; Johansson JE; Lodding P; Kylmälä T; Lundmo P; Klarskov P; Tammela TL; Tasdemir I; Morris T; Armstrong J;
Scand J Urol Nephrol; 2006; 40(6):441-52. PubMed ID: 17130095
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of adjuvant hormonal therapy.
Mcleod DG
Urology; 2002 Sep; 60(3 Suppl 1):13-20; discussion 21. PubMed ID: 12231039
[TBL] [Abstract][Full Text] [Related]
19. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
[TBL] [Abstract][Full Text] [Related]
20. Delaying/reducing the risk of clinical tumour progression after primary curative procedures.
Wirth M
Eur Urol; 2001; 40 Suppl 2():17-23. PubMed ID: 11684860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
